UBS Adds Over 3 Million Shares of MPW to its Holdings

Hospital Stocks News

According to a recent Form 13F filing submitted to the SEC, UBS Group AG disclosed a noteworthy and bullish investment in MPW stock. Here’s what you need to know about Medical Properties Trust, Inc., as well as UBS Group AG and their long position in shares of MPW stock:

About UBS Group AG

UBS Group AG (NYSE: UBS) is an international investment banking and financial services firm founded and based in Switzerland, maintaining a dominant presence in all major financial centers around the globe.

About Medical Properties Trust, Inc. (MPW)

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world’s largest owners of hospitals with 431 facilities and roughly 43,000 licensed beds in nine countries and across four continents on a pro forma basis. MPT’s financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations.

UBS Group AG Buys Stock in MPW

According to the most recent 13F filed by UBS Group AG, the firm added 3,234,770 shares of MPW stock to it holdings in the recent quarter. That brings their total long position in Medical Properties Trust, Inc. to 3,659,903 shares, representing approximately 0.6110% of the 598,982,979 MPW shares outstanding. Based on the most recent closing price of $11.24 per share of MPW, the entire UBS Group AG position in Medical Properties Trust, Inc. is worth roughly $41,137,309.72.

Summary

Be sure to check out more recent 13F filings here to stay up to date on the latest disclosures from institutional investment managers like UBS Group AG. Also be sure to check out more recent 13F filing analysis news here.

Subscribe

Don't miss a market-moving update!

Please wait...

Thank you for subscribing! 

Responses

Your email address will not be published. Required fields are marked *